Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lymphoma 1Hodgkin Disease 1Hematologic Diseases 1Endometrial Neoplasms 1Burkitt Lymphoma 1

Interventions

blinatumomab 2Vincristine 2Rituximab 2Methotrexate 2Cytarabine 2Cyclophosphamide 2prednylidene 1pegaspargase 1merphos 1dexamethasone acetate 1dexamethasone 21-phosphate 1deltacortene 1azathiopurine 1auricularum 1X-Rays 1Stem Cell Transplantation 1Spinal Puncture 1Specimen Handling 1Prednisone 1Phantoms, Imaging 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Mercaptopurine 1Leucovorin 1Etoposide 1Doxorubicin 1Dexamethasone 1Daunorubicin 1Calcium Dobesilate 1CT-P10 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Burkitt Lymphoma × Doxorubicin × Clear all
NCT01516580 2026-02-09

Intergroup Randomized Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Rituximab Evaluation in High Risk Patients

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Completed
482 enrolled 1 FDA
Lymphoid

Burkitt Lymphoma, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡